SG11201809100QA - Use of gram negative species to treat atopic dermatitis - Google Patents

Use of gram negative species to treat atopic dermatitis

Info

Publication number
SG11201809100QA
SG11201809100QA SG11201809100QA SG11201809100QA SG11201809100QA SG 11201809100Q A SG11201809100Q A SG 11201809100QA SG 11201809100Q A SG11201809100Q A SG 11201809100QA SG 11201809100Q A SG11201809100Q A SG 11201809100QA SG 11201809100Q A SG11201809100Q A SG 11201809100QA
Authority
SG
Singapore
Prior art keywords
international
atopic dermatitis
gram negative
bethesda
pharmaceutical compositions
Prior art date
Application number
SG11201809100QA
Other languages
English (en)
Inventor
Ian Myles
Sandip Datta
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of SG11201809100QA publication Critical patent/SG11201809100QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201809100QA 2016-04-19 2017-04-18 Use of gram negative species to treat atopic dermatitis SG11201809100QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662324762P 2016-04-19 2016-04-19
PCT/US2017/028133 WO2017184601A1 (en) 2016-04-19 2017-04-18 Use of gram negative species to treat atopic dermatitis

Publications (1)

Publication Number Publication Date
SG11201809100QA true SG11201809100QA (en) 2018-11-29

Family

ID=58708000

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809100QA SG11201809100QA (en) 2016-04-19 2017-04-18 Use of gram negative species to treat atopic dermatitis

Country Status (11)

Country Link
US (8) US10195236B2 (enExample)
EP (2) EP3445330B1 (enExample)
JP (1) JP2019513769A (enExample)
KR (1) KR102340006B1 (enExample)
CN (1) CN109310626A (enExample)
AU (2) AU2017253935B2 (enExample)
CA (1) CA3020863A1 (enExample)
IL (1) IL262455A (enExample)
MX (1) MX2018012719A (enExample)
SG (1) SG11201809100QA (enExample)
WO (1) WO2017184601A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6494233B2 (ja) * 2013-10-03 2019-04-03 日東電工株式会社 粘膜ワクチン組成物
CN115919906A (zh) 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
EP3445330B1 (en) 2016-04-19 2022-07-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of gram negative species to treat atopic dermatitis
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
EP3720458A4 (en) 2017-12-05 2021-12-08 BioPlx, Inc. METHODS AND COMPOSITIONS FOR PREVENTING MICROBIAL INFECTION
AU2019253714A1 (en) 2018-04-10 2020-11-26 Siolta Therapeutics, Inc. Microbial consortia
EP3784260A4 (en) * 2018-04-18 2022-03-09 Forte Subsidiary, Inc. Compositions for the treatment of skin conditions
KR20210013080A (ko) * 2018-05-11 2021-02-03 포르테 서브시디어리, 인크. 피부 병태의 치료를 위한 조성물
WO2020023072A1 (en) * 2018-07-23 2020-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
KR102691625B1 (ko) 2022-04-19 2024-08-06 코스맥스 주식회사 세디미니박테리움 락티스 균주 및 그의 피부 상태 개선 용도
KR102691627B1 (ko) 2022-04-19 2024-08-06 코스맥스 주식회사 로제오모나스 뮤코사 균주 및 그의 피부 상태 개선 용도
CN115140846B (zh) * 2022-07-06 2024-06-21 江苏聚庚科技股份有限公司 一种复合处理剂、制备方法及其在净化废水中的应用
CN116139163B (zh) * 2023-03-22 2023-09-05 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种粘液玫瑰单胞菌胞外多糖在制备用于缓解特应性皮炎的药物上的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1019523A (en) 1910-03-14 1912-03-05 Maxmillian E Primbs Ironing-table.
US1020695A (en) 1911-11-17 1912-03-19 Hess Mfg Co Drier.
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4829000A (en) 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
AU692486B2 (en) 1993-10-22 1998-06-11 Smithkline Beecham Corporation Pharmaceutical or veterinary composition comprising mupirocin or a salt thereof in a cream base
US6645506B1 (en) * 1997-04-18 2003-11-11 Ganeden Biotech, Inc. Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil
ES2284247T3 (es) 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
WO2003011261A1 (en) 2001-08-01 2003-02-13 Medlogic Global Limited Cyanoacrylate monomer-containing antibiotic formulation for topical use
US20030100034A1 (en) 2001-10-16 2003-05-29 Millennium Pharmaceuticals, Inc. 9136, a human aldehyde dehydrogenase family member and uses therefor
DE10158712A1 (de) 2001-11-29 2003-06-26 Umwelttechnik Georg Fritzmeier Zusammensetzung zur Behandlung der Hautoberfläche
KR100536522B1 (ko) * 2003-03-07 2005-12-14 (주)바이오솔루션 인간 피부 유래의 신규한 박테리오신 및 여드름치료제로서의 용도
WO2006036406A2 (en) 2004-08-25 2006-04-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Live microbial microbicides
JP2006131622A (ja) 2004-10-05 2006-05-25 Genichiro Soma 薬剤
KR20070091613A (ko) 2004-11-08 2007-09-11 그렌마크 파머수티칼스 엘티디. 항여드름 화합물 및 항생제 화합물을 함유하는 국소적 제약조성물
EP1736537A1 (en) 2005-06-22 2006-12-27 OrganoBalance GmbH Methods and means for protecting the skin against pathogenic microorganisms
FR2942719B1 (fr) 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
AU2010268647B2 (en) 2009-06-30 2015-01-15 Derman Biomedicine Co. Ltd. Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
DK2704704T3 (en) 2011-05-03 2019-01-14 Dupont Nutrition Biosci Aps PROBIOTIC BACTERIES FOR TOPICAL TREATMENT OF SKIN DISORDERS
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
IN2014DN07752A (enExample) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
EP2899096B1 (en) 2013-01-15 2017-07-26 NSK Ltd. Tilt-type steering device
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2015160911A2 (en) 2014-04-15 2015-10-22 Aobiome Llc Ammonia-oxidizing nitrosomonas eutropha strain d23
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US9526201B2 (en) 2015-01-05 2016-12-27 Cnh Industrial America Llc Twin-row planter with tandem driven seed meters
US10774305B2 (en) 2015-04-20 2020-09-15 S-Biomedic Nv Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
EP3445330B1 (en) 2016-04-19 2022-07-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of gram negative species to treat atopic dermatitis
US10695386B2 (en) 2017-05-11 2020-06-30 Shayne K. Morris Skin microbiome colonizer formulations and methods for use
EP3784260A4 (en) 2018-04-18 2022-03-09 Forte Subsidiary, Inc. Compositions for the treatment of skin conditions
KR20210013080A (ko) 2018-05-11 2021-02-03 포르테 서브시디어리, 인크. 피부 병태의 치료를 위한 조성물
WO2020023072A1 (en) 2018-07-23 2020-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis

Also Published As

Publication number Publication date
AU2021215132A1 (en) 2021-09-02
KR102340006B1 (ko) 2021-12-20
EP3445330A1 (en) 2019-02-27
US20190142874A1 (en) 2019-05-16
US10195236B2 (en) 2019-02-05
US20190076486A1 (en) 2019-03-14
AU2017253935A1 (en) 2018-11-01
US10946048B2 (en) 2021-03-16
CA3020863A1 (en) 2017-10-26
US20190192580A1 (en) 2019-06-27
US10682379B2 (en) 2020-06-16
KR20190003582A (ko) 2019-01-09
EP3445330B1 (en) 2022-07-06
US20190142873A1 (en) 2019-05-16
US20190381112A1 (en) 2019-12-19
WO2017184601A1 (en) 2017-10-26
CN109310626A (zh) 2019-02-05
AU2017253935B2 (en) 2021-07-29
US10946049B2 (en) 2021-03-16
MX2018012719A (es) 2019-05-30
EP3903766A1 (en) 2021-11-03
US20180296612A1 (en) 2018-10-18
IL262455A (en) 2018-12-31
JP2019513769A (ja) 2019-05-30
US10980846B2 (en) 2021-04-20
US20180214495A1 (en) 2018-08-02
US20190343895A1 (en) 2019-11-14
US10206957B2 (en) 2019-02-19

Similar Documents

Publication Publication Date Title
SG11201809100QA (en) Use of gram negative species to treat atopic dermatitis
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201906301UA (en) Methods of manufacture of nut flours and formulations for oral immunotherapy
SG11201903514VA (en) Novel cd47 monoclonal antibodies and uses thereof
SG11201909325RA (en) 2-amino-quinoline derivatives
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201906222WA (en) Jak1 selective inhibitors
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901374WA (en) Antibiotic compounds
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201805001UA (en) Method of treating influenza a
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201804255QA (en) Treatment of intrahepatic cholestasis and related liver diseases
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases